Total revenue for the full year 2025 reached $172.4 million, a substantial increase from $23.7 million in 2024. Revuforj net revenue for the full year 2025 was $124.8 million, with $44.2 million in Q4 2025, representing a 38% quarter-over-quarter increase. Niktimvo net revenue for the full year 2025 was $151.6 million (reported by Incyte), contributing $42.4 million in collaboration revenue to Syndax, with $19.4 million in Q4 2025, a 22% quarter-over-quarter increase. The company reported a net loss attributable to common stockholders of $285.4 million, or $3.29 per share, for the full year 2025, an improvement from a $318.8 million net loss in 2024. Cash, cash equivalents, and short-term investments stood at $394.1 million as of December 31, 2025. Enrollment was completed in the Phase 2 IPF trial of axatilimab, with topline data expected in Q4 2026. Syndax initiated REVEAL-ND, a Phase 3 trial for revumenib in newly diagnosed NPM1m AML patients, in November 2025. The company expects total research and development plus selling, general and administrative expenses for 2026 to be approximately $400 million, excluding $50 million in estimated non-cash stock compensation expense. Syndax anticipates its operating expense base to remain stable over the next couple of years and expects to reach profitability with current cash and anticipated revenues.